Limited capability for testing mycobacterium tuberculosis for susceptibility to new drugs

Hamzah Z. Farooq, Daniela M. Cirillo, Doris Hillemann, David Wyllie, Marieke J. Van der Werf, Csaba Ködmön, Vladyslav Nikolayevskyy*

*Corresponding author for this work

Research output: Contribution to journalLetterpeer-review

2 Citations (Scopus)

Abstract

We surveyed availability of phenotypic drug susceptibility testing for drug-resistant Mycobacterium tuberculosis in Europe. Of 27 laboratories, 17 tested for linezolid, 11 for clofazimine, 9 for bedaquiline, and 6 for delamanid during 2019. Our findings indicate that testing capacity for newer and repurposed tuberculosis drugs exists, but its availability is limited.

Original languageEnglish
Pages (from-to)985-987
Number of pages3
JournalEmerging Infectious Diseases
Volume27
Issue number3
DOIs
Publication statusPublished - Mar 2021

Bibliographical note

Funding Information:
This study was supported by the European Centre for Disease Prevention and Control (grant no. ECDC/ GRANT/2018/001).

Publisher Copyright:
© 2021 Centers for Disease Control and Prevention (CDC). All rights reserved.

Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.

Fingerprint

Dive into the research topics of 'Limited capability for testing mycobacterium tuberculosis for susceptibility to new drugs'. Together they form a unique fingerprint.

Cite this